Table 3.

Stakeholders’ agreement on the benefits and limitations of a mobile health approach in multimorbid patients with polypharmacy such as the heart transplant population (N=26).

Statement for agreement		Stakeholders, n (%)
Benefits
	Improves patients’ knowledge of therapy, management, and medication adherence	23 (88)
	Improves the continuity of care and the flow of information between providers and levels of care	21 (81)
	Allows patients to be empowered and actively manage their disease and treatment	20 (77)
	Resolves patient and caregiver queries from home due to the two-way health care provider-patient communication	20 (77)
	Monitoring and managing patient-reported outcomes such as symptoms and adverse effects to drugs	17 (65)
	Focuses on health promotion and prevention to reduce the number of acute events	17 (65)
	Increases the cost-effectiveness of resources by reducing both scheduled and urgent visits due to decompensation	17 (65)
	Facilitates innovation in health and documentation of evidence that translates into measurable health outcomes	17 (65)
	Reduces inequalities in access to the health system due to traveling difficulties or lack of resources	10 (38)
	Improves patients’ experience because of close communication with providers	4 (15)
Limitations
	Increase in workload for staff	15 (58)
	Lack of institutional guidelines to set up and implement systems and accreditation of mobile health apps	14 (54)
	Risk of not sharing the patient’s registered information with other levels of care or with other apps (used to manage other health conditions)	13 (50)
	Risk of not protecting confidential patient data	6 (23)
	Risk of creating inequalities in patient care due to resistance to use technology or the digital divide	6 (23)
	Lack of guarantee of the long-term economic sustainability of research projects for innovative technologies and companies that develop the systems	4 (15)